CI 976

Key Product Details

Product Description

CI 976 is a selective acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor (IC₅₀ = 0.073 μM). Lowers non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol concentrations in rats with pre-established dyslipidemia. Orally active. Also inhibits Golgi-associated LPL acyltransferase (LPAT) activity (IC₅₀ = 15 μM).

Product Specifications for CI 976

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CI 976

The following data is based on the product molecular weight 393.57.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.54 mL	12.70 mL	25.41 mL
5 mM	0.51 mL	2.54 mL	5.08 mL
10 mM	0.25 mL	1.27 mL	2.54 mL
50 mM	0.05 mL	0.25 mL	0.51 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Sliskovic and White Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. TiPS.
• Drecktrah Inhibition of a Golgi complex lysophospholipid acyltransferase induces membrane tubule formation and retrograde trafficking. Mol.Biol.Cell
• Krause In vivo evidence that the lipid-regulating activity of ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J.Lipid Res. 1993 PMID: 8429262

Product Documents for CI 976